Fjarde AP Fonden Fourth Swedish National Pension Fund Trims Holdings in Pfizer Inc. (NYSE:PFE)

Fjarde AP Fonden Fourth Swedish National Pension Fund decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 40.9% during the first quarter, Holdings Channel reports. The fund owned 794,271 shares of the biopharmaceutical company’s stock after selling 549,500 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Pfizer were worth $20,127,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Clarity Asset Management Inc. purchased a new position in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. purchased a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Finally, Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. BMO Capital Markets reduced their target price on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. The Goldman Sachs Group boosted their price target on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. HSBC dropped their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Finally, Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.12.

Pfizer Price Performance

NYSE PFE opened at $25.14 on Thursday. The business’s fifty day moving average price is $24.52 and its 200-day moving average price is $24.47. The stock has a market capitalization of $142.93 billion, a price-to-earnings ratio of 13.37, a PEG ratio of 0.88 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.